Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLC5508 + QL2107 vs Tislelizumab + Chemotherapy in First-line Extensive-stage Small Cell Lung Cancer
NCT07802821Phase 3Recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Oct 2026
- Primary completion
- Mar 2029
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of MHB088C and QL2107 in small cell lung cancer (SCLC) (2 arms), sponsored by Qilu Pharmaceutical. Primary endpoint: Overall Survival at 36 months. Started Oct 2026; status: recruiting.
02
Drugs
MHB088CQL2107
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07802821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07802821.